1	Severe cognitive decline in long-term care is related to gut microbiome production of
2	metabolites involved in neurotransmission, immunomodulation, and autophagy
3	
4	Andrew P. Shoubridge <sup>1,2</sup> , Lucy Carpenter <sup>1,2</sup> , Erin Flynn <sup>1</sup> , Lito E. Papanicolas <sup>1,2,3</sup> , Josephine
5	Collins <sup>1</sup> , David Gordon <sup>3,4</sup> , David J. Lynn <sup>2,5</sup> , Craig Whitehead <sup>6,7</sup> , Lex E.X. Leong <sup>3</sup> , Monica
6	Cations <sup>7,8</sup> , David P. De Souza <sup>9</sup> , Vinod K. Narayana <sup>9</sup> , Jocelyn M. Choo <sup>1,2</sup> , Steve L.
7	Wesselingh <sup>1,2,7</sup> , Maria Crotty <sup>6,7</sup> , Maria C. Inacio <sup>7,10</sup> , Kerry Ivey <sup>1,11</sup> , Steven L. Taylor <sup>1,2#</sup> ,
8	Geraint B. Rogers <sup>1,2#*</sup>
9	
10	<sup>1</sup> Microbiome and Host Health Program, South Australian Health and Medical Research
11	Institute, Adelaide, SA, Australia.
12	<sup>2</sup> Infection and Immunity, Flinders Health and Medical Research Institute, College of
13	Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
14	<sup>3</sup> SA Pathology, Adelaide, SA, Australia.
15	<sup>4</sup> Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford
16	Park, SA, Australia.
17	<sup>5</sup> Computational & Systems Biology Program, South Australian Health and Medical Research
18	Institute, Adelaide, SA, Australia.
19	<sup>6</sup> Department of Rehabilitation, Aged and Palliative Care, Flinders Medical Centre, Flinders
20	University, Bedford Park, SA, Australia.
21	<sup>7</sup> Registry of Senior Australians, South Australian Health and Medical Research Institute,
22	Adelaide, SA, Australia.
23	<sup>8</sup> College of Education, Psychology and Social Work, Flinders University, Bedford Park, SA,
24	Australia
25	<sup>9</sup> Bio21 Institute and Department of Biochemistry and Molecular Biology, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Melbourne, Parkville, VIC, Australia.

- <sup>10</sup> Allied Health and Human Performance, University of South Australia, Adelaide, SA,
- 28 Australia.
- <sup>11</sup> Department of Nutrition, Harvard University T.H. Chan School of Public Health, Boston,
- 30 MA, USA.
- 31
- <sup>#</sup> These authors share senior authorship.
- <sup>\*</sup>Correspondence:
- 34 Professor Geraint B. Rogers
- 35 Director, Microbiome & Host Health, South Australian Health and Medical Research
- 36 Institute, North Terrace, Adelaide, SA 5001, Australia.
- 37 geraint.rogers@sahmri.com
- **38** +61 (0)403 558251

# 39 Summary

Ageing-associated cognitive decline affects more than half of those in long-term residential 40 41 aged care. Emerging evidence suggests that gut microbiome-host interactions influence the effects of modifiable risk factors. We investigated the relationship between gut microbiome 42 characteristics and severity of cognitive impairment (CI) in 159 residents of long-term aged 43 care. Severe CI was associated with a significantly increased abundance of proinflammatory 44 45 bacterial species, including Methanobrevibacter smithii and Alistipes finegoldii, and decreased relative abundance of beneficial bacterial clades. Severe CI was associated with increased 46 47 microbial capacity for methanogenesis, and reduced capacity for synthesis of short-chain fatty acids, neurotransmitters glutamate and gamma-aminobutyric acid, and amino acids required 48 for neuro-protective lysosomal activity. These relationships were independent of age, sex, 49 antibiotic exposure, and diet. Our findings implicate multiple gut microbiome-brain pathways 50 in ageing-associated cognitive decline, including inflammation, neurotransmission, and 51 autophagy, and highlight the potential to predict and prevent cognitive decline through 52 microbiome-targeted strategies. 53

54

# 55 Keywords

56 Aged care, microbiome, cognitive impairment, microbiome-gut-brain axis.

# 57 Introduction

Progressive loss of cognitive function is a common feature of ageing and is not limited to those 58 with dementia (Albert et al., 1995; Comijs et al., 2004; Harada et al., 2013; Verdi et al., 2018). 59 Contributory pathologies, often occurring in combination, include ischaemic or haemorrhagic 60 infarcts within the brain (characteristic of vascular dementia) (Henon et al., 2001; Ye et al., 61 2015), the accumulation of amyloid plaques and neurofibrillary tangles (characteristic of 62 63 Alzheimer's disease) (Bussian et al., 2018; Luo et al., 2020), and the development of abnormal collections of alpha-synuclein protein within diseased brain neurons (characteristic of Lewy 64 65 body dementia) (Lin et al., 2017; Mattila et al., 2000). While these pathophysiological processes are increasingly well-characterised, the factors that contribute to them and their 66 relationship to external risk exposures remain poorly understood. 67

68

In addition to genetic factors (Koistinaho et al., 2004; Lin et al., 2018; Liu et al., 2017; Parcon 69 et al., 2018; Shi et al., 2017; Ulrich et al., 2018), modifiable risk factors associated with 70 71 dementia have been identified. Modifiable risk factors include exposures (smoking, excessive alcohol consumption, physical inactivity, air pollution, diet); health conditions (hypertension, 72 obesity, depression, diabetes, traumatic brain injury, hearing impairment), and social factors 73 74 (less education, and low social contact) (Livingston et al., 2020). Together, these modifiable risk factors are estimated to account for 40% of dementia incidence (Livingston et al., 2020). 75 Identifying how such factors influence the pathophysiology of ageing-associated cognitive 76 impairment (CI) is essential to the development of effective prevention and treatment. 77

78

The gut microbiome influences neurophysiology, central nervous system, and cognitive
function through discrete bidirectional pathways, collectively termed the microbiome-gutbrain axis (Cryan et al., 2019; Rogers et al., 2016; Sharon et al., 2016; Shoubridge et al., 2022).

These pathways include the microbial synthesis of neurotransmitters, such as gamma-82 aminobutyric acid (GABA), noradrenaline, dopamine and serotonin (Valles-Colomer et al., 83 2019; Yano et al., 2015), the modulation of systemic immunity (Correa-Oliveira et al., 2016; 84 Dalile et al., 2019), and metabolism of essential amino acids, such as tyramine and tryptophan 85 (Lai et al., 2021; Marx et al., 2021). They also involve production of immune and metabolically 86 active metabolites, such as short-chain fatty acids (SCFAs) and 4-ethylphenylsulfate, and 87 88 activation of nerve growth factor, glial-derived neurotrophic factor, and brain-derived neurotrophic factor secretion (Bonfili et al., 2021; Soto et al., 2018). Such microbial traits have 89 90 the potential to contribute substantially to the development of neurological diseases, including Alzheimer's (Kim et al., 2020; Vogt et al., 2017), Huntington's (Bjorkqvist et al., 2008; Du et 91 al., 2020; Wasser et al., 2020), and Parkinson's diseases (Sampson et al., 2016; Sun et al., 92 2018). 93

94

Ageing-associated gut microbiome characteristics (Claesson et al., 2011; Meyer et al., 2022) 95 96 are linked to progressive frailty and cognitive decline (Komanduri et al., 2021; Manderino et al., 2017; Meyer et al., 2022; Verdi et al., 2018). External exposures that disrupt the 97 microbiome, such as antibiotics, can further contribute to altered neurological homeostasis and 98 poorer cognitive outcomes (Desbonnet et al., 2015; Frohlich et al., 2016; Lynn et al., 2021). In 99 contrast, dietary interventions that alter the composition of the gut microbiome in a beneficial 100 101 manner can result in improvements in cognitive function (Ghosh et al., 2020). Such findings suggest that the relationship between the gut microbiome and host neurophysiology may 102 provide a basis to predict and/or prevent the onset and progression of ageing-associated 103 cognitive decline. Potential causality in these relationships is suggested by studies that have 104 successfully recapitulated impairment of memory and synaptic plasticity following faecal 105 microbiota transplant from aged mice to younger mice (D'Amato et al., 2020). 106

- 108 Our aim was to explore whether the severity of CI experienced by residents of long-term aged
- 109 care facilities (sometimes referred to as nursing homes, care homes, or residential aged care
- 110 facilities) is associated with characteristics of the gut microbiome, and if so, whether such
- 111 relationships might provide mechanistic insight into CI pathogenesis.

### **112 Materials and Methods**

# 113 Study design, cohort and data collection

114 The Generating evidence on Resistant bacteria in the Aged Care Environment (GRACE) study (www.gracestudy.com.au) was a cohort study supported by the Australian Medical Research 115 Future Fund (Grant No. GNT1152268). Ethical approval for the study was obtained from the 116 Southern Adelaide Clinical Human Research Ethics Committee (HREC/18/SAC/244). The 117 118 GRACE study investigated the carriage and transfer of resistant bacteria in long-term aged care facilities and was conducted between 2018 and 2020. GRACE enrolled 279 residents in five 119 120 long-term aged care facilities in metropolitan South Australia. Anonymised participant data, including assessments of cognition and behaviour, were collected via an entry into care funding 121 assessment (Aged Care Funding Instrument [ACFI]), in addition to medications prescribed via 122 the Pharmaceutical Benefits Scheme (PBS) (Carpenter, 2021). 123

124

# 125 Assessment of cognitive impairment

The Cognitive Skills component of the ACFI was used as a basis for assessment of cognitive 126 impairment. This cognitive skills component assesses a person's cognitive abilities in everyday 127 activities, including memory, self-care, and orientation (AIHW, 2002; Department of Health 128 and Ageing, 2016), as defined via the Psychogeriatric Assessment Scales - Cognitive 129 Impairment Scales (PAS-CIS) method (Jorm et al., 1995). Where individuals were unable to 130 undertake the PAS-CIS test, for example, non-English speaking, sensory impairment, or severe 131 cognitive impairment beyond the scope of the instrument, the ACFI cognitive skills assessment 132 was based on a clinical report by a registered health professional (Department of Health and 133 Ageing, 2016). The ACFI cognitive skills component utilised the PAS-CIS and/or clinical 134 reports to rate an individual's level of cognitive impairment as none or minimal (PAS-CIS = 135 0-3), mild (4-9), moderate (10-15), or severe (16-21). 136

137

# 138 Cognitive impairment cohort

139 GRACE participants were categorised according to their cognitive skills rating, as defined in the ACFI. Participants were excluded if: 1) their cognitive skills assessment was not completed 140 or missing, 2) the date of stool collection was not known, 3) the date of the cognitive assessment 141 was not known, 4) the participant was diagnosed with a developmental or intellectual disability, 142 143 or 5) the period between cognitive skills assessment and stool sample collection was not known or was deemed an outlier (>1462 days as determined using the ROUT method of regression 144 145 and outlier removal (Motulsky & Brown, 2006)). A total of 45 participants were excluded (detailed in **Supplementary Fig. 1**). Participants with dementia and a missing PAS-CIS rating 146 were imputed the median PAS-CIS value from their cognitive skills assessment group. Mental 147 and behavioural diagnoses of dementia, depression, and delirium were ascertained from the 148 ACFI, where a documented diagnosis from a medical practitioner was provided. 149

150

# 151 Faecal collection, DNA extraction, metagenomic sequencing and bioinformatics

Stool was collected and stored using Norgen Stool Nucleic Acid Collection and Preservation 152 Tubes (Norgen Biotek, ON, Canada) and microbial DNA extracted using the PowerLyzer 153 PowerSoil DNA Isolation Kit (Qiagen, Hilden, Germany) as described previously (Carpenter, 154 2021). Indexed, paired-end DNA libraries were prepared using the Nextera XT DNA Library 155 Prep Kit (Illumina, CA, USA), as per manufacturer's instructions. Samples were sequenced at 156 a depth of 5 Gb on an Illumina Novaseq platform with 150bp paired-end reads. Forward and 157 158 reverse sequences were quality-filtered using Trimmomatic (v0.39) and human reads were removed with Bowtie (v2.3.5.1) against the NCBI human reference genome release GRCh38 159 (Bolger et al., 2014; Langmead & Salzberg, 2012). Taxonomic relative abundance was 160 assigned using MetaPhlAn (v3.0) (Beghini et al., 2021), while microbial metabolic pathway 161

abundance was assigned using HUMAnN (v3.0) against the MetaCyc database (Beghini et al.,
2021). Sequence data has been entered into the European Nucleotide Archive (ENA) at EMBLEBI under accession number PRJEB51408.

165

# 166 Microbiome characterisation

The taxonomic relative abundance at the species level was used to generate alpha diversity (within-group) and beta diversity (between-group) measures. Alpha diversity measures included Pielou's evenness (J': a score between 0-1 where scores are influenced more by the evenness of abundant species), the Shannon-Wiener diversity (H'): a score of the number and equal representation of different types of species (Peet, 1974), and species richness (d: total number of unique species identified per participant), and were generated using the 'vegan' R package (Oksanen, 2022).

174

The Bray-Curtis index was calculated to compare microbiome similarity between groups (beta diversity), using square-root transformed species relative abundance data (PRIMER 6 (v6.1.16)). For sensitivity analysis, weighted and unweighted UniFrac distance matrices (Lozupone & Knight, 2005) were calculated using the "calculate\_unifrac" MetaPhlAn R script (Beghini et al., 2021). Non-metric multidimensional scaling (nMDS) plots for all beta diversity measures were generated using the 'vegan' package in R and visualised using 'ggplot2'.

181

# 182 Microbial functional profiling

The functional capacity of the gut microbiota was defined by the genetically encoded functional traits detected within the metagenome. These MetaCyc pathways from HUMAnN were filtered to only analyse those present in >30% of participants. Two functional profiling analyses were performed: an untargeted analysis of all filtered pathways (n=400), and a targeted analysis

based on pathways with a hypothesised functional role in cognitive impairment (n=70). These included pathways involved in neurotransmitter biosynthesis (n=2), SCFA production (n=25), and amino acid biosynthesis (n=43).

190

# 191 Metabolite profiling

As a confirmatory analysis of microbial functional capacity, the metabolomic profile of a 192 193 randomly selected subgroup of individuals (n=35; n=11-12/group) was established. Stool metabolite analysis was performed on an Agilent 1200 series high-performance liquid 194 195 chromatography system (Agilent Technologies) (methods modified from (Gubert et al., 2022; Kong et al., 2021) and detailed in Supplementary Text 1). Briefly, metabolite extraction and 196 analysis were performed separately for SCFAs and polar metabolites. SCFAs analysis was 197 performed using an Agilent 6490 series triple quadrupole mass spectrometer (Agilent 198 Technologies) while polar metabolites (a screen for 165 low molecular weight metabolites, e.g. 199 amino acids) were analysed using an Agilent 6545 series quadrupole time-of-flight mass 200 spectrometer (Agilent Technologies). Resultant data matrices were imported to the web-based 201 platform MetaboAnalyst (v5.0) for quality control checks. SCFA data were normalised to 202 203 internal standards, and polar metabolite data were log-transformed and median-normalised.

204

# 205 Covariates

Covariates were: days since cognitive assessment (below or equal/above the median), age (low, medium or high tertile), sex (male or female), medication history (Pharmaceutical Benefits Scheme (PBS) data available or unavailable), medications that affect gastrointestinal health and are prevalent in aged care facilities: antibiotic use (yes or no); proton pump inhibitor use (yes or no); opioid use (yes or no); laxative use (yes or no), meal texture at time of cognitive assessment (regular or soft/smooth), and liquid texture at time of cognitive assessment

(normal/thin or thick). Medication use was defined as two or more supplies to a resident within90 days prior to stool collection.

214

# 215 Statistical analysis

Both unadjusted and multivariate regression models were applied in all analyses. Multivariate
adjusted models accounted for time between cognitive assessment and stool collection, age,
sex, antibiotics, proton pump inhibitors, opioids, laxatives, meal texture, and liquid texture (as
detailed above).

220

Beta diversity analysis was performed using permutational multivariate analyses of variance (PERMANOVA) on Bray-Curtis, weighted, and unweighted UniFrac distance matrices in an unrestricted permutation of raw data. Only the Bray-Curtis metric was assessed with the multivariate-adjusted model. PERMANOVA analyses were performed using PRIMER 6, with 9999 permutations.

226

Within-individual microbiome variables included alpha diversity, phyla-level relative 227 abundance (only those detected in >30% of participants), species-level relative abundance 228 (only those detected in >30% of participants), metabolic pathway abundance (only those 229 detected in >30% of participants), and metabolite intensities. All within-individual variables 230 were converted to groups consisting of: zero values, tertile 1, tertile 2, and tertile 3. Ordinal 231 logistic regression was performed to assess the effect of CI on microbiome variables using the 232 'MASS' function in R. The odds ratios and 95% confidence intervals for the coefficients of the 233 regression models were calculated and tested for statistical significance (p < 0.05) as CI severity 234 increased, using the PAS-CIS score of cognitive impairment as the predictor variable. False 235 Discovery Rate (FDR) multiple hypothesis testing was conducted with the Benjamini and 236

- Hochberg method across all profiles using the 'p.adjust' function in R, at a significant threshold
- of 0.05. Correlations between microbial functional capacity and detected metabolites were
- calculated by two-tailed Spearman correlations and tested for statistical significance (p < 0.05).

# 240 **Results**

The study group of 159 participants did not differ from the original GRACE cohort in any of 241 the assessed characteristics (Supplementary Table 1). CI was classified as mild in 46 242 individuals (28.9%) with a median PAS-CIS score of 6.6 (IQR=5.0-8.0), moderate in 58 243 (36.5%; PAS-CIS median=11.0; IQR=11.0-12.8), and severe in 55 (34.6%; PAS-CIS 244 median=18.0; IQR=17.0-18.8) (Table 1; Supplementary Fig. 2A). The median time from 245 246 assessment of cognitive skills to the subsequent collection of stool samples was 437 days (IQR: 185-741). Participant age, sex ratio, time since cognitive assessment, and use of antibiotics, 247 248 opioids, and laxatives, did not differ significantly between CI severity categories (p>0.05; Supplementary Fig. 2B-F). However, the number of days that an individual had been residing 249 in long-term aged care was significantly higher for those in the severe CI group (median=939 250 days; IQR=219-854) compared to the mild CI group (median=500 days; IQR=130-627; 251 p < 0.05). Proton pump inhibitor usage was significantly lower in the severe CI group (p < 0.05). 252 Within the severe CI group, 53/55 (96.4%) had a concurrent diagnosis of dementia, 33/58 253 (56.9%) of moderate CI had a dementia diagnosis, and 4/46 (8.7%) of those with mild CI. 254

255

# 256 Gut microbiome characteristics differ by CI severity


Gut microbiome characterisation of long-term aged care residents with CI was determined by 257 metagenomic sequencing of collected stool samples (Fig. 1A). A total of 11 bacterial phyla 258 were detected across the 159 stool samples, consisting of 186 genera (586 species). The 259 composition and distribution of taxa was broadly similar with previous studies of aged 260 populations (Claesson et al., 2011; Jackson et al., 2016), with high representation of 261 262 Eggerthella lenta, Escherichia coli, Faecalibacterium prausnitzii, and Clostridium species (Fig. 1B), and genera within the Bacteroidota (formerly Bacteroides) and Bacillota 263 264 (Firmicutes) phyla (**Fig. 1C**).

## 265

Demographic	Mild	Moderate	Severe	Total (n=159)	
Demographic	( <b>n=46</b> )	( <b>n=58</b> )	(n=55)		
Age (years):					
Median (IQR)	87.5 (81.3;93.6)	90.3 (83.7;95.0)	87.9 (82.0;93.0)	88.7(82.1; 93.5)	
Sex: n (%)					
Female	27 (58.7)	42 (72.4)	40 (72.7)	109 (68.6)	
Male	19 (41.3)	16 (27.6)	15 (27.3)	50 (31.4)	
PAS-CIS:					
Median (IQR)	6.6 (5.0;8.0)	11.0 (11.0;12.8)	18.0 (17.0;18.8)	10.8 (7.0;18.0)	
Time between CI					
assessment and stool					
collection (days):					
Median (IQR)	345.5 (148.5,654.5)	421.5 (182.3,734.3)	487.0 (252.0,909.0)	437.0 (185.0,741.0)	
Time since entry to					
facility (days):					
Median (IQR)	500 (253.0,947.5)	704 (299.0,983.0)	962 (502.0,1198.0)	681 (360.0,1015.0)	
Dementia diagnosis:					
% (n) <sup>#</sup>	8.7 (4)	56.9 (33)	96.4 (53)	56.6 (90)	
Memory Support					
<b>Unit^:</b> n (%)	0 (0.0)	4 (6.9)	19 (34.5)	23 (14.5)	
Meal texture: n (%)					
Regular	38 (82.6)	44 (75.9)	30 (54.5)	112 (70.4)	
Soft/smooth	8 (17.4)	14 (24.1)	25 (45.5)	47 (29.6)	
Liquid texture: n (%)					
Normal/thin	42 (91.3)	54 (93.1)	49 (89.1)	145 (91.2)	
Thick	4 (8.7)	4 (6.9)	6 (10.9)	14 (8.8)	
Antibiotics (at least 2 supplied <sup>*</sup> ): n (%)	10 (21.7)	7 (12 1)	5 (0 1)	22(12.9)	
Proton pump	10 (21.7)	7 (12.1)	5 (9.1)	22 (13.8)	
inhibitors (at least 2					
supplied <sup>*</sup> ): n (%)	23 (50.0)	23 (39.7)	12 (21.8)	58 (36.5)	
Opioids (at least 2			(21.0)		
supplied <sup>*</sup> ): n (%)	8 (17.4)	12 (20.7)	14 (25.5)	34 (21.4)	
Laxatives (at least 2				Ì, í	
supplied <sup>*</sup> ): n (%)	6 (13.0)	6 (10.3)	9 (16.4)	21 (13.2)	

266

- **Table 1.** Study Cohort Characteristics by Severity of Cognitive Impairment.
   267
- <sup>#</sup>Extracted from Aged Care Funding Instrument data. 268
- 269 ^Memory support units (also known as dementia units/wards, memory care, or special care
- units) are secure areas within long-term care facilities specially designed to accommodate 270
- residents with dementia. 271
- \*Medication use defined as two or more supplies of the same medication within 90 days prior 272
- to stool collection. 273



Adjusted odds ratio with 95% confidence interval

### Figure 1. Gut microbiome of residents of long-term aged care facilities stratified by

cognitive impairment (CI). A) Characterisation of the gut microbiome of long-term aged care 277 residents with cognitive impairment determined by metagenomic sequencing of collected stool 278 samples. **B**) Taxa bar plot of core species grouped by cognitive impairment severity (present 279 in >60% of participants). Species coloured by phyla: Actinomycetota = blues; Bacteroidota = 280 oranges; Bacillota = greens; Pseudomonadota = purples; non-core species (other) = grey. C) 281 282 The frequency of genera detected and their median relative abundances, labelled with core genera. **D**) Non-metric multidimensional scaling plot of Bray-Curtis similarity matrix, grouped 283 284 by CI severity (mild, n=46; moderate, n=58; severe, n=55), showing significant divergence between CI groups following multivariate analysis (p(perm)=0.0003). E) Odds ratio and 95% 285 confidence interval of effect of CI severity on microbiome diversity (taxa richness, Shannon-286 Wiener diversity, and Pielou's evenness), following multivariate analysis. Multivariate 287 analysis adjusted for time since CI assessment, age, sex, antibiotic use, proton pump inhibitor 288 use, opioid use, laxative use, recorded medical history, meal texture, and liquid texture. ns=not 289 significant; \*\*q<0.01; \*\*\*q<0.001 for adjusted p-values following FDR correction. 290

291 Following adjustment for time since cognitive assessment, age, sex, medication use, and diet, the faecal microbiota composition differed significantly between mild, moderate, and severe 292 CI (p(perm)=0.0003; R<sup>2</sup>=2.21%; Fig. 1D; Table 2). This difference was greatest between 293 severe CI and mild CI (p(perm)=0.0023), and severe CI and moderate CI (p(perm)=0.0003), 294 and consistent with the unadjusted model (Table 2). Repeated analysis using weighted and 295 unweighted UniFrac dissimilarity did not identify significant intergroup differences, apart from 296 297 between mild and moderate CI groups using weighted UniFrac dissimilarity (unadjusted p(perm)=0.037; Supplementary Fig. 4). 298

299

Analysis of microbiota diversity identified a positive association between CI severity and taxa richness (odds ratio (OR): 1.08 [95% confidence interval 1.05, 1.12], q<0.001) and Shannon-Wiener diversity (OR: 1.043 [1.013, 1.073], q<0.05; **Fig. 1E**). However, there was no association between CI severity and Pielou's evenness (OR: 0.985 [0.957, 1.014], q>0.05; **Fig. 1E**).

305

To assess whether specific taxa differed with CI, phylum-level and species-level relative 306 abundances were assessed. Of the seven phyla present in at least 30% of participants, five 307 differed significantly with CI (Fig. 2). Pseudomonadota (Proteobacteria) (OR: 0.937 [0.909, 308 0.965], q<0.001) and Bacillota (OR: 0.943 [0.915, 0.971], q<0.001) were lower with increasing 309 310 CI severity (Fig. 2). In contrast, Euryarchaeota (OR: 1.097 [1.065, 1.131], q<0.001), Actinomycetota (Actinobacteria) (OR: 1.066 [1.035, 1.099], q<0.001), and Synergistota 311 (Synergistetes) (OR: 1.043 [1.008, 1.079], q<0.05) were higher with increasing CI severity 312 (Fig. 2). 313

314

315

medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286878; this version posted January 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a	CC-	BY-N	C-ND	4.0	International	license	
------------------------------	-----	------	------	-----	---------------	---------	--


	Unadjusted Model			Multivariate-adjusted Model <sup>a</sup>			
Main Test	Pseudo-F Ratio	R <sup>2</sup>	p(perm)^	Pseudo-F Ratio	R <sup>2</sup>	p(perm)^	
Cognitive Impairment*	ognitive Impairment* 1.9646 0.0246		0.0002	1.815	0.0221	0.0003	
Pairwise Test	t		p(perm)^	t		p(perm)^	
Mild v Moderate	1.0596		0.2583	1.1135		0.1478	
Mild v Severe	1.4474 1.6304		0.0017	1.4228		0.0023	
Moderate v Severe			0.0002	1.5265		0.0003	

316

- **Table 2.** Permutational ANOVA of the gut microbiome by severity of cognitive impairment.
- <sup>a</sup>Time since cognitive impairment assessment + age + sex+ antibiotic use + proton pump
- 319 inhibitor use + opioid use + laxative use + recorded medication history + meal texture + liquid

320 texture.

- 321 ^Permutation p-value generated with a PERMANOVA.
- 322 \*Degrees of freedom = 2.



Adjusted odds ratio with 95% confidence interval

323

Figure 2. Phyla-level differences in the gut microbiome of residents of long-term aged 324 care by cognitive impairment. Odds ratio and 95% confidence interval of effect of cognitive 325 impairment severity on phyla relative abundance. Colours indicate bacterial phyla: blue = 326 Actinomycetota; green = Bacillota; purple = Pseudomonadota; grey = non-core species. 327 328 Performed by multivariate analysis, adjusting for time since cognitive impairment assessment, age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use, recorded medical 329 history, meal texture, and liquid texture. #Denotes phyla with recently amended names: 330 Actinomycetota (Actinobacteria), Synergistota (Synergistetes), Bacillota (Firmicutes), and 331 Pseudomonadota (Proteobacteria). \*q<0.05; \*\*\*q<0.001 for adjusted p-values following FDR 332 333 correction.

Bacterial species that were detected in at least 60% of participants, and with a relative abundance of at least 0.1%, were denoted as "core" taxa (**Supplementary Table 2**). Of the 586 microbial species identified across the entire cohort, 30 were identified as core in mild CI (**Supplementary Fig. 5A**), 31 in moderate CI (**Supplementary Fig. 5B**), and 29 in severe CI (**Supplementary Fig. 5C**).

339

340 Comparison of species relative abundances identified 50 species that differed significantly with CI severity (Fig. 3A). Notably, Blautia hydrogentrophica (OR: 1.135 [1.099, 1.173]), 341 342 Catabacter hongkongensis (OR: 1.131 [1.096, 1.168]), and Alistipes finegoldii (OR: 1.089 [1.058, 1.121]), had the strongest positive association with CI severity (all q<0.001, Fig. 3A). 343 Further, Collinsella aerofaciens and Methanobrevibacter smithii were not only positively 344 associated with CI severity (q<0.001, Fig. 3A), they were also core species in severe CI, but 345 not mild or moderate (Fig. 3B, Supplementary Table 2, Supplementary Fig. 5). In contrast, 346 *Bacteroides uniformis* (OR: 0.935 [0.908, 0.962]), *Blautia producta* (OR: 0.916 [0.888, 0.945]) 347 and *Blautia wexlerae* (OR: 0.940 [0.913, 0.968]) were among those with the strongest inverse 348 association with CI severity (all q<0.001, Fig. 3A). Faecalibacterium prausnitzii, a species 349 previously associated with health outcomes in ageing (Jackson et al., 2016), was also found to 350 trend lower in this cohort with increasing CI severity, but this did not achieve statistical 351 significance (OR: 0.986 [0.958, 1.014], q=0.421, Fig. 3A; p>0.05, Fig. 3B). 352

medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286878; this version posted January 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

353

### 90 70 50 30 Α в Relation of species to severity of cognitive impairment relative abundance) Alistipes finegoldii q-value 30 Blautia hydrogenotrophica \*\*\* Catabacter hongkongensis \*\*\* 20 Clostridium disporicum \*\*\* Lachnospira pectinoschiza-Christensenella minuta-10 Alistipes finegoldii-Methanobrevibacter smithii-Actinomyces sp. oral taxon 448-Mild Moderate Severe Firmicutes bacterium CAG:145-Ruminococcus bromii-90 70 50 30 \*\*\* Alistipes indistinctus Collinsella aerofaciens 4 (relative abundance) Ruminococcus bicirculans-30 Collinsella stercoris-Collinsella aerofaciens-Eisenbergiella tayi-20 B Eubacterium ventriosum-٠ Eubacterium callanderi-10 Coprobacillus cateniformis-Bacteroides vulgatus-Hungatella hathewayi-Mild Moderate Severe Parabacteroides merdae-Clostridium leptum \*\*\* 90 70 50 30 Ruminococcus torques-Methanobrevibacter smithii (relative abundance) Butyricimonas virosa-\*\* Intestinibacter bartlettii-\* 30 Mogibacterium diversum-\* Ruminococcaceae bacterium D5-\* 20 Coprococcus comes-\* Gordonibacter pamelaeae-\* Streptococcus anginosus group-\* 10 Streptococcus mutans-\* Eubacterium hallii-\* Mild 0 Alistipes shahii-\* Moderate Severe 75 species with q>0.05 not shown 90 70 50 30 Streptococcus salivarius-\* Clostridium innocuum \* Bacteroides uniformis \*\*\* (relative abundance) Erysipelatoclostridium ramosum 30 Streptococcus thermophilus-\* Streptococcus oralis-\* 20 Enterorhabdus caecimuris-\* Clostridium symbiosum Clostridium clostridioforme-10 999 Clostridium citroniae Blautia wexlerae 0 Bacteroides uniformis-Mild Moderate Severe Clostridium lavalense-90 70 50 30 Faecalibacterium prausnitzii Clostridium bolteae-Streptococcus parasanguinis-(relative abundance) Rothia dentocariosa-30 · Oscillibacter sp. 57\_20-Blautia producta ns \*\*\* 20 0.9 1.1 1.2 0.8 1.0 Negative Positive 10 relation relation



Moderate Severe 21

Mild

## 354 Figure 3. Species-level differences in the gut microbiome of residents of long-term aged


care by cognitive impairment. A) Odds ratio and 95% confidence interval of effect of 355 cognitive impairment severity on species relative abundance. Colours indicate bacterial phyla: 356 blue = Actinomycetota; orange = Bacteroidota; green = Bacillota = green; grey = other. 357 Performed by multivariate analysis, adjusting for time since cognitive impairment assessment, 358 age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use, recorded medical 359 360 history, meal texture, and liquid texture. B) The relative abundance of bacterial species associated with cognitive impairment severity and aging: Alistipes finegoldii, Collinsella 361 362 aerofaciens, Methanobrevibacter smithii, Bacteroides uniformis, and Faecalibacterium prausnitzii. ns=not significant; \*q<0.05; \*\*q<0.01; \*\*\*q<0.001 for adjusted p-values 363 following FDR correction. Mild, n=46; moderate, n=58; severe, n=55. 364

# 365 The functional capacity and output of the gut microbiota differs with CI severity


Differences in the functional capacity of the gut microbiota were identified with increasing CI 366 severity. Four hundred MetaCyc pathways were detected in >30% of participants, of which, 70 367 were selected based on their potential influence on CI, including via mechanisms relating to 368 neurotransmission, immunity, and metabolism. Metabolomic analysis of a subgroup of 369 individuals (n=35; n=11-12/group) confirmed these findings (Fig. 4A). A total of 165 polar 370 371 metabolites were detected in stool samples from these participants, including 33 metabolites classed as amino acids, peptides, and analogues, 50 classed as lipids and lipid-like molecules, 372 373 18 classed as carbohydrates, and 64 classed within other categories (Supplementary Fig. 6A), in addition to nine SCFAs (Supplementary Fig. 6B). Pathways inversely associated with CI 374 severity included PWY-5505, a pathway essential to the production of the primary excitatory 375 376 neurotransmitter glutamate (OR: 0.922 [0.895, 0.949], q<0.001), and GLUDEG-I-PWY, a pathway essential to the production of the primary inhibitory neurotransmitter GABA (OR: 377 0.962 [0.934, 0.990], q<0.05, Fig. 4B). The metabolite and excitatory neurotransmitter 378 glutamate was present at lower levels in individuals with severe CI (Fig. 4C). Similarly, 379 pathways related to the production of immunomodulatory SCFAs, including acetate (P461-380 PWY; OR: 0.877 [0.850, 0.904], q<0.001), propionate (P108-PWY; OR: 0.939 [0.913, 0.966], 381 q<0.001), and butyrate (PWY-5022; OR: 0.935 [0.908, 0.962], q<0.001, Fig. 4D) were also 382 lower in relative abundance as CI severity increased. The decrease in immune functional 383 capacity corresponded with depleted levels of immunomodulating SCFA metabolites in 384 individuals with severe CI, including for butyrate (q<0.01), propionate (q<0.01), and acetate 385 (q<0.05, Fig. 4E; Supplementary Fig. 7). Functional pathways related to the biosynthesis of 386 amino acids that regulate key metabolic processes, such as autophagy, included L-arginine 387 (PWY-5154; OR: 0.911 [0.884, 0.938], q<0.001), L-lysine, L-threonine, and L-methionine 388 (P4-PWY; OR: 0.905 [0.878, 0.932], q<0.001), and were among the most depleted at higher 389

CI severity (Fig. 4F). Production of amino acid polar metabolites also decreased with
increasing CI severity (Fig. 4G; Supplementary Fig. 7).

393	Further exploratory analysis across all functional pathways (n=400) identified 271 statistically
394	significantly altered pathways, with multiple pathways related to methanogenesis among those
395	of greatest significance and higher relative abundance (p<0.01, Fig. 4F; q<0.001,
396	Supplementary Table 3). The relative abundances of metagenomic pathways and the levels
397	of associated metabolites were also positively correlated (Supplementary Fig. 8).



It is made available under a



402

Figure 4. Specific functional differences relating to neurotransmission, immunity, and 403 metabolism in the gut microbiome of residents of long-term aged care by cognitive 404 405 **impairment.** A) Metagenomic and metabolomic profiling of microbiome functional capacity and output for long-term aged care residents with cognitive impairment in relation to neuronal 406 communication (B-C), immunity (D-E), and metabolism (F-G). Odds ratio and 95% 407 confidence interval of effect of cognitive impairment severity on functional pathway relative 408

409 abundance and metabolite normalised abundance. Performed by multivariate analysis, adjusting for time since cognitive impairment assessment, age, sex, antibiotic use, proton pump 410 inhibitor use, opioid use, laxative use, recorded medical history, meal texture, and liquid 411 texture. The abundance of key pathways and metabolites grouped by cognitive impairment 412 severity involved in neurotransmission, immunomodulation, and metabolism are shown. 413 ns=not significant; \*q<0.05; \*\*q<0.01; \*\*\*q<0.001 for adjusted p-values following FDR 414 415 correction. Pathways: mild, n=46; moderate, n=58; severe, n=55. Metabolites: mild, n=12; moderate, n=11; severe, n=12. 416

# 417 **Discussion**

We report significant associations between characteristics of the faecal microbiome and the 418 419 severity of CI in residents of long-term aged care facilities. Microbiome CI severity-associated traits were identified even after adjustment for age, sex, prior medication exposure, and diet. 420 Individuals with more severe CI exhibited a greater representation of the Actinomycetota 421 phylum and Methanobrevibacter smithii, and a lower prevalence of Bacteroides uniformis, a 422 423 reduced capacity for synthesis of SCFAs, neurotransmitters (glutamate and GABA), and amino acids that are essential for autophagy, and an increased capacity for methanogenesis. These 424 425 findings identify microbial factors potentially influencing ageing-associated cognitive decline, and present opportunities for prediction and treatment of CI. 426

427

Changes in intestinal microbiology can influence neuroplastic changes in the brain via a range 428 of mechanisms (Cryan et al., 2019; Rogers et al., 2016; Sharon et al., 2016; Shoubridge et al., 429 2022). Many of these pathways relate to the production of specific factors by the gut 430 microbiota, including the biosynthesis of immunomodulatory 431 metabolites and neurotransmitters (Correa-Oliveira et al., 2016; Erny et al., 2015), amino acid metabolism 432 (Bellono et al., 2017; Ye et al., 2021), and the release of pro-inflammatory cytokines (Arentsen 433 et al., 2017; Erny et al., 2015; Kim et al., 2013). 434

435

We assessed the potential influence of the gut microbiome of participants to neurophysiology through two complementary strategies. The first was the analysis of the metagenome, representing the functional capacity of microbes within the gut to produce particular metabolites. The second was a confirmatory analysis of the faecal metabolome, representing the output of the combined metabolic activity of the gut microbiota. Each of these processes identified factors that were significantly associated with CI severity, and notably, positive

442 correlations between metabolite levels and the prevalence of genes involved in their443 biosynthesis was widespread.

444

A lower capacity for microbial biosynthesis of the neurotransmitters, glutamate and GABA, 445 was evident in those with more severe CI. Levels of both factors have been associated with CI 446 previously (Gueli & Taibi, 2013; Jimenez-Jimenez et al., 1998; Lin et al., 2019; Lin et al., 447 448 2017; Murley et al., 2020). The gut microbiome mediates neurological homeostasis via multiple key pathways, including through metabolism and production of neurotransmitters, 449 450 such as glutamate, GABA, dopamine, and serotonin. These neurotransmitters can then directly innervate intestinal neural pathways or circulate peripherally to the brain (Kaelberer et al., 451 2018; Shoubridge et al., 2022; Strandwitz, 2018). 452

453

Severe CI was also associated with reduced capacity for bacterial biosynthesis of the SCFAs 454 butyrate, acetate, and propionate. SCFA production is known to be important for normal 455 cognitive function and in preventing neuroinflammation (Arnoldussen et al., 2017; Byrne et 456 al., 2016; Erny et al., 2015). Previous studies have identified an association between a reduced 457 458 capacity for SCFA biosynthesis and the development of a chronic and systemic inflammatory state, commonly referred to as "inflammaging", involving increased circulation of IL-6, TNF-459 a, and C-reactive protein (Franceschi & Campisi, 2014; Franceschi et al., 2018; Frasca & 460 Blomberg, 2016). Inflammaging, particularly in the brain, is associated with decreased 461 neuronal arborisation, numbers of neurons and synapses, and overall brain cortical volume 462 (Stephenson et al., 2018) and has been implicated in the acceleration of dementia onset (Grande 463 et al., 2021; Sankowski et al., 2015), and the rate of neurological deterioration (Eikelenboom 464 et al., 2012; Giunta et al., 2008). 465

In contrast to a decreased capacity for SCFA synthesis, we observed a greater capacity for 467 methanogenesis with increasing CI severity. This relationship was apparent from the 468 representation of methanogenic pathways within the metagenome, and from the increased 469 relative abundance of species, such as Methanobrevibacter smithii, in those with severe CI. 470 Increasing capacity for methanogenesis within the gut microbiome has been reported 471 previously in two cohorts of centenarians (Li et al., 2022; Wu et al., 2019), as well as in rodent 472 473 models of ageing (Maczulak et al., 1989). While the clinical consequences of increased methane production in the gut are poorly understood, high levels are associated with functional 474 475 constipation (Chatterjee et al., 2007), diverticulosis (Weaver et al., 1986), and colon cancer (Haines et al., 1977). 476

477

The gut microbiome in participants with more severe CI was found to be depleted in its capacity 478 to synthesise amino acids, particularly L-arginine. The availability of arginine is critical to the 479 regulation of autophagy (Poillet-Perez et al., 2018), the cellular process that involves the 480 recycling of nutrients from macromolecules in response to nutrient deficiency (Mizushima, 481 2004) and the removal of damaged material from the cellular environment (Lazarou et al., 482 2015). Genetic polymorphisms in genes involved in the regulation of autophagy have been 483 linked to a number of neurodegenerative diseases, including Alzheimer's, Parkinson's, 484 Huntington's, and Lewy body diseases, frontotemporal dementia, and amyotrophic lateral 485 sclerosis (Fujikake et al., 2018; Gan et al., 2018; Gao et al., 2018; Nixon, 2013; Tsuang et al., 486 2012). The conversion of arginine to putrescine, spermidine, and spermine by intestinal 487 microbes promotes autophagy (Eisenberg et al., 2009; Oliphant & Allen-Vercoe, 2019; Pugin 488 et al., 2017) and the significant reduction in arginine biosynthesis capacity is consistent with 489 the contribution of suppressed autophagy to the development and progression of age-related 490 disease. Severe CI was also associated with a reduced capacity for microbial production of the 491

essential amino acids, L-valine and L-lysine. Impaired L-valine production has been linked
with declining neurological health previously (Baranyi et al., 2016), and diet supplementation
with L-lysine and L-valine has been shown to improve cognitive and psychological function in
older adults (Suzuki et al., 2020).

496

Microbial functions, such as those associated with CI severity, can often be performed by many 497 498 different members of the gut microbiota. This phenomenon is referred to as functional redundancy and can result in relationships between individual microbial species and host 499 500 measures of disease being less strong than those based on conserved microbial functional traits. Despite this, we observed a number of discrete bacterial taxa that were significantly associated 501 with CI. In particular, Methanobrevibacter smithii and Alistipes finegoldii were more prevalent 502 503 in those with severe CI, while Bacteroides uniformis was less highly represented. As above, Methanobrevibacter smithii is associated with higher methane production (Ghoshal et al., 504 2016) and has been identified as an inflammatory and cardiometabolic biomarker (Fu et al., 505 2020). Whilst the precise mechanisms of *Alistipes* species in health and disease are still unclear 506 (Parker et al., 2020), clinical studies of inflammatory diseases have shown Alistipes finegoldii 507 triggers intestinal inflammation and decreases SCFA-producing bacteria, potentially playing a 508 pathogenic role in chronic diseases (Kim et al., 2018; Parker et al., 2020; Rodriguez-Palacios 509 et al., 2019). 510

511

We also observed severe CI to be associated with a lower prevalence of bacterial taxa that are considered broadly beneficial. These included *Bacteroides uniformis*, which is associated with reduced risk of colorectal cancer (Wang et al., 2012) and inflammatory bowel disease (Takahashi et al., 2016), and *Blautia* species, which have the potential to inhibit the growth of pathogenic bacteria in the intestine and reduce inflammation (Hosomi et al., 2022; Liu et al.,

2021). Taxa that have been previously associated with aspects of cognition, such as *Collinsella aerofaciens* (Ghosh et al., 2020), were more prevalent in those with severe CI. However, other
bacterial taxa associated with aspects of ageing, frailty, and cognitive decline in previous
studies, including *Faecalibacterium prausnitzii* (Jackson et al., 2016), *Eubacterium rectale*(Ghosh et al., 2020; van Soest et al., 2020), and *Escherichia coli* (Barrientos et al., 2009;
d'Avila et al., 2018; Hoogland et al., 2018) were not associated with CI severity in our cohort.

In addition to the relative abundance of different bacterial species, analysis of the broad 524 525 structure of the gut microbiota can also be informative. We assessed three different alpha diversity measures, Shannon-Wiener diversity, Pielou's evenness, and species richness, that 526 together provide an overview of microbiota structure. While evenness, which represents the 527 528 relative differences in the abundance of various species in the community, was not associated significantly with CI severity, Shannon-Wiener diversity and species richness were both higher 529 in severe CI. Studies of the gut microbiota in ageing have previously reported reduced diversity 530 in older age. For example, Verdi and colleagues identified significantly lower faecal microbiota 531 diversity to be associated with longer reaction times (in cognitive assessments) in an 532 independently living aged cohort (Verdi et al., 2018). Similarly, Wasser and colleagues 533 reported reduced alpha diversity in those with Huntington's disease (Wasser et al., 2020), while 534 two other studies have reported no significant relationship between CI severity and alpha 535 diversity (Komanduri et al., 2021; Stadlbauer et al., 2020). In our analysis, where age was 536 adjusted for, a contrary effect was observed, consistent with an association between CI and 537 538 specific microbiome changes that is separate to wider microbial shifts that are typical in later life. 539

Our study strengths and limitations include the use of entry into long term care facility 541 assessment tools ('ACFI') for CI ascertainment. While it has been employed by the Australian 542 543 Commonwealth Government as a basis for care funding for all residents of long term care facilities across Australia since 2008, is completed by trained assessors, and includes the PAS-544 CIS (a validated and consistently applied tool of CI in aged care), there are limitations to this 545 tool. For example, people may not be comprehensively assessed for CI if they have a 546 547 sensory/speech impairment, are non-English speaking, or have severe CI beyond the scope of the instrument, which can include a concurrent diagnosis of dementia or mental disorder 548 549 (AIHW, 2002; Department of Health and Ageing, 2016). The ACFI is also designed for funding purposes, not clinical care or epidemiological surveillance, which likely results in 550 underreporting of these chronic health conditions (Lind et al., 2020). 551

552

CI was measured on average 16 months prior to stool collection. There was no clinically significant difference in mean time from assessment to stool collection between severity groups, and the period of time between assessment and sample collection could not be reduced further without substantial reduction in the cohort size. However, changes in cognition between assessment and stool sample collection could confound the relationships that we report. Future studies arising from our findings would benefit from a briefer and more consistent interval between CI and microbiome assessment, and/or longitudinal analysis of associations.

560

561 Our study had other limitations that should be considered. First, we were able to relate changes 562 in intestinal microbiology to cognitive function, but not to specific aspects of host neurological 563 pathophysiology. Second, the relationships identified between taxonomic and functional 564 features of the intestinal microbiome and CI are associative and whether they contribute 565 directly to the development and progression of CI remains to be established. Third, the

possibility that CI severity drives alterations in microbiome composition, mediated by factors such as dementia medications, changes in food preparation for those with dysphagia, and isolation to locked wards for residents with severe behavioural care needs, cannot be excluded based on the current analysis. Indeed, changes in behaviour associated with psychiatric conditions in other contexts, particularly those relating to diet, have been shown to contribute to disease-specific gut microbiome markers (Larroya et al., 2021).

572

573 While our analysis involved participants from five facilities in metropolitan South Australia, 574 the findings are likely to be representative of a wider phenomenon. Alignment of the GRACE 575 cohort to the comprehensive Registry of Senior Australians (ROSA) (Carpenter et al., 2023), a 576 cohort that includes over 2.8 million Australians (including those in long-term aged care) 577 supported the representative nature of our study cohort (Carpenter et al., 2023).

578

# 579 Conclusions

We report age-, sex-, antibiotic-, and diet-independent microbial markers of severe CI. Our analysis implicates multiple gut microbiome-brain pathways in ageing-associated cognitive decline, including those involved in inflammation, neurotransmission, and autophagy. These findings raise the possibility of identifying cognitive decline and slowing its rate of progression via microbiome-targeted therapeutic interventions.

585

# 586 DECLARATIONS

# 587 Ethics approval and consent to participate

Ethical approval for the study was obtained from the Southern Adelaide Clinical Human
Research Ethics Committee (HREC/18/SAC/244). Participants provided written informed

consent themselves or where third-party consent was required, a legal guardian or familymember with power of attorney provided consent on their behalf.

592

- 593 **Consent for publication**
- 594 Not applicable.
- 595

# 596 Data availability statement

The GRACE study data are available upon reasonable request. GRACE study data described 597 598 in this article are available to all interested researchers through collaboration. Please contact GBR (geraint.rogers@sahmri.com). The metagenomic data for this study have been deposited 599 in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number 600 601 PRJEB51408 (https://www.ebi.ac.uk/ena/browser/view/PRJEB51408). The metabolomic data for this study is available at the NIH Common Fund's National Metabolomics Data Repository 602 (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org 603 (Sud et al., 2016), where it has been assigned Project ID PR001631. The metabolomic data can 604 also be accessed directly via its Project DOI: http://dx.doi.org/10.21228/M8W43G. Regarding 605 the sharing of linked data from ROSA, due to data custodian restrictions, individual ROSA 606 data cannot be made publicly available to other researchers. 607

608

# 609 **Declaration of interests**

- 610 The authors declare that they have no competing interests, nor any financial or personal
- relationships with other people or organisations that could bias this study.

612

613 Funding

This research was supported by an Australian Medical Research Future Fund (MRFF) grant 614 from the Australian Department of Health (GNT1152268). The Australian Department of 615 Health reviewed the study proposal, but did not play a role in study design, data collection, 616 analysis, interpretation, or manuscript writing. GBR is supported by a National Health and 617 Medical Research Council (NHMRC) Senior Research Fellowship (GNT1155179) and a 618 Matthew Flinders Professorial Fellowship. MCI is supported by The Hospital Research 619 620 Foundation Mid-Career Fellowship (MCF-27-2019) and NHMRC Investigator Grant (GNT119378). DJL is supported by an EMBL Australia Group Leader Award. SLT is 621 622 supported by an NHMRC Emerging Leadership grant (GNT2008625).

623

# 624 Authors' contributions

APS, LC, EF, LEP, MaC, MCI, KI, SLT, and GBR conceived and designed the study. APS,
LC, EF, and JC acquired the clinical samples and clinical data. APS and LC acquired the
metagenomic data. APS, DPDS and VKN acquired the metabolomic data. APS, LC, EF, JMC,
KI, SLT, GBR analysed and interpreted the data. APS, LC, KI, SLT, and GBR drafted the
manuscript. All authors provided intellectual input to the manuscript and critically revised the
manuscript. All authors have read and approved the final version of the manuscript.

631

# 632 Acknowledgments

This project used NCRIS-enabled Metabolomics Australia infrastructure at the University of
Melbourne funded through BioPlatforms Australia. This project used the Metabolomics
Workbench/National Metabolomics Data Repository (NMDR) supported by the NIH (U2CDK119886) and Common Fund Data Ecosystem (CFDE) (3OT2OD030544).

## References 637

- Australian Institute of Health and Welfare (AIHW). (2002). Aged care assessment program 638 data dictionary. Canberra, Australia. 639
- Albert, M. S., Jones, K., Savage, C. R., Berkman, L., Seeman, T., Blazer, D., & Rowe, J. W. 640 (1995). Predictors of cognitive change in older persons: MacArthur studies of 641 successful aging. Psychol Aging, 10(4), 578-589. https://doi.org/10.1037//0882-642 7974.10.4.578 643
- Arentsen, T., Qian, Y., Gkotzis, S., Femenia, T., Wang, T., Udekwu, K., Forssberg, H., & Diaz 644 645 Heijtz, R. (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates behavior. 646 brain development and Mol Psychiatry, 22(2), 257-266. https://doi.org/10.1038/mp.2016.182 647
- 648 Arnoldussen, I. A. C., Wiesmann, M., Pelgrim, C. E., Wielemaker, E. M., van Duyvenvoorde, W., Amaral-Santos, P. L., Verschuren, L., Keijser, B. J. F., Heerschap, A., Kleemann, 649 R., Wielinga, P. Y., & Kiliaan, A. J. (2017). Butyrate restores HFD-induced adaptations 650 in brain function and metabolism in mid-adult obese mice. Int J Obes (Lond), 41(6), 651 652 935-944. https://doi.org/10.1038/ijo.2017.52
- Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Rothenhausler, H. B., Theokas, S., 653 Robier, C., Mangge, H., Reicht, G., Hlade, P., & Meinitzer, A. (2016). Branched-Chain 654 655 Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Disorder. **PLoS** One, e0160542. Mood 11(8), 656 https://doi.org/10.1371/journal.pone.0160542 657
- Barrientos, R. M., Watkins, L. R., Rudy, J. W., & Maier, S. F. (2009). Characterization of the 658 sickness response in young and aging rats following E. coli infection. Brain Behav 659 Immun, 23(4), 450-454. https://doi.org/10.1016/j.bbi.2009.01.016 660
- Beghini, F., McIver, L. J., Blanco-Miguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, 661 A., Manghi, P., Scholz, M., Thomas, A. M., Valles-Colomer, M., Weingart, G., Zhang, 662 Y., Zolfo, M., Huttenhower, C., Franzosa, E. A., & Segata, N. (2021). Integrating 663 taxonomic, functional, and strain-level profiling of diverse microbial communities with 664 bioBakery 3. Elife, 10. https://doi.org/10.7554/eLife.65088 665
- Bellono, N. W., Bayrer, J. R., Leitch, D. B., Castro, J., Zhang, C., O'Donnell, T. A., Brierley, 666 S. M., Ingraham, H. A., & Julius, D. (2017). Enterochromaffin Cells Are Gut 667 Chemosensors that Couple to Sensory Neural Pathways. Cell, 170(1), 185-198 e116. 668 https://doi.org/10.1016/j.cell.2017.05.034 669
- Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, 670 671 R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., 672 Leavitt, B. R., Moller, T., & Tabrizi, S. J. (2008). A novel pathogenic pathway of 673 immune activation detectable before clinical onset in Huntington's disease. J Exp Med, 674 205(8), 1869-1877. https://doi.org/10.1084/jem.20080178 675
- Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina 676 677 sequence data. Bioinformatics, 30(15), 2114-2120. https://doi.org/10.1093/bioinformatics/btu170 678
- Bonfili, L., Cecarini, V., Gogoi, O., Gong, C., Cuccioloni, M., Angeletti, M., Rossi, G., & 679 Eleuteri, A. M. (2021). Microbiota modulation as preventative and therapeutic 680 approach in Alzheimer's disease. FEBS J, 288(9), 2836-2855. 681 https://doi.org/10.1111/febs.15571 682
- 683 Bussian, T. J., Aziz, A., Meyer, C. F., Swenson, B. L., van Deursen, J. M., & Baker, D. J. (2018). Clearance of senescent glial cells prevents tau-dependent pathology and 684

685	cognitive decline. <i>Nature</i> , 562(7728), 578-582. <u>https://doi.org/10.1038/s41586-018-</u>
686 687	<u>0543-y</u> Byrne, C. S., Chambers, E. S., Alhabeeb, H., Chhina, N., Morrison, D. J., Preston, T., Tedford,
688	C., Fitzpatrick, J., Irani, C., Busza, A., Garcia-Perez, I., Fountana, S., Holmes, E.,
689	Goldstone, A. P., & Frost, G. S. (2016). Increased colonic propionate reduces
690	anticipatory reward responses in the human striatum to high-energy foods. Am J Clin
691	Nutr, 104(1), 5-14. https://doi.org/10.3945/ajcn.115.126706
692	Carpenter, L., Shoubridge, A. P., Flynn, E., Lang, C., Taylor, S. L., Papanicolas, L. E., Collins,
693	J., Gordon, D., Lynn, D. J., Crotty, M., Whitehead, C., Leong, L. E. X., Wesselingh, S.
694	L., Ivey, K., Inacio, M. C., & Rogers, G. B. (2023). Cohort profile: GRACE - a
695	residential aged care cohort examining factors influencing antimicrobial resistance
696	carriage. BMC Geriatr, 23(1), 521. https://doi.org/10.1186/s12877-023-04215-3
697	Carpenter, L., Shoubridge, A., Flynn, E., Taylor, S. Ivey, K., Rogers, G. on behalf of the
698	GRACE Investigative Study Team. (2021). Generating evidence on Resistant Bacteria
699	in the Aged Care Environment (GRACE) 2021 Report. SAHMRI.
700	https://www.gracestudy.com.au/post/grace-study-stage-2-report
701	Chatterjee, S., Park, S., Low, K., Kong, Y., & Pimentel, M. (2007). The degree of breath
702	methane production in IBS correlates with the severity of constipation. Am J
703	Gastroenterol, 102(4), 837-841. https://doi.org/10.1111/j.1572-0241.2007.01072.x
704	Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E.,
705	Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., Stanton, C., van Sinderen, D.,
706	O'Connor, M., Harnedy, N., O'Connor, K., Henry, C., O'Mahony, D., Fitzgerald, A. P.,
707	Shanahan, F., Twomey, C., Hill, C., Ross, R. P., & O'Toole, P. W. (2011). Composition,
708	variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl
709	Acad Sci U S A, 108 Suppl 1, 4586-4591. https://doi.org/10.1073/pnas.1000097107
710	Comijs, H. C., Dik, M. G., Deeg, D. J., & Jonker, C. (2004). The course of cognitive decline
711	in older persons: results from the longitudinal aging study amsterdam. Dement Geriatr
712	Cogn Disord, 17(3), 136-142. <u>https://doi.org/10.1159/000076346</u>
713	Correa-Oliveira, R., Fachi, J. L., Vieira, A., Sato, F. T., & Vinolo, M. A. (2016). Regulation of
714	immune cell function by short-chain fatty acids. Clin Transl Immunology, 5(4), e73.
715	https://doi.org/10.1038/cti.2016.17
716	Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme,
717	M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E.,
718	Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A.,
719	Moloney, G., Morelli, E., Morillas, E., O'Connor, R., Cruz-Pereira, J. S., Peterson, V.
720	L., Rea, K., Ritz, N. L., Sherwin, E., Spichak, S., Teichman, E. M., van de Wouw, M.,
721	Ventura-Silva, A. P., Wallace-Fitzsimons, S. E., Hyland, N., Clarke, G., & Dinan, T.
722	G. (2019). The Microbiota-Gut-Brain Axis. <i>Physiol Rev</i> , 99(4), 1877-2013.
723 724	https://doi.org/10.1152/physrev.00018.2018 D'Amete A Di Casera Manaelli I Lugarini E Man A L La Call C Brance I L V
724 725	D'Amato, A., Di Cesare Mannelli, L., Lucarini, E., Man, A. L., Le Gall, G., Branca, J. J. V., Chalardini, C. Amadai, A. Partalli, E. Pagali, M. Pagini, A. Lugioni, C. Callina, P.
725 726	Ghelardini, C., Amedei, A., Bertelli, E., Regoli, M., Pacini, A., Luciani, G., Gallina, P., Altera, A., Narbad, A., Gulisano, M., Hoyles, L., Vauzour, D., & Nicoletti, C. (2020).
720	
727 728	Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related
728 729	proteins in young recipients. <i>Microbiome</i> , 8(1), 140. <u>https://doi.org/10.1186/s40168-</u>
730	020-00914-w
,	

d'Avila, J. C., Siqueira, L. D., Mazeraud, A., Azevedo, E. P., Foguel, D., Castro-Faria-Neto,
H. C., Sharshar, T., Chretien, F., & Bozza, F. A. (2018). Age-related cognitive impairment is associated with long-term neuroinflammation and oxidative stress in a

mouse model of episodic systemic inflammation. J Neuroinflammation, 15(1), 28. 734 https://doi.org/10.1186/s12974-018-1059-y 735 Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019). The role of short-chain 736 fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol, 737 16(8), 461-478. https://doi.org/10.1038/s41575-019-0157-3 738 Department of Health and Ageing. (2016). Aged care funding instrument (ACFI) user guide. 739 Canberra, Australia. 740 Desbonnet, L., Clarke, G., Traplin, A., O'Sullivan, O., Crispie, F., Moloney, R. D., Cotter, P. 741 742 D., Dinan, T. G., & Cryan, J. F. (2015). Gut microbiota depletion from early 743 adolescence in mice: Implications for brain and behaviour. Brain Behav Immun, 48, 165-173. https://doi.org/10.1016/j.bbi.2015.04.004 744 Du, G., Dong, W., Yang, Q., Yu, X., Ma, J., Gu, W., & Huang, Y. (2020). Altered Gut 745 746 Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease. Front Immunol, 11, 603594. https://doi.org/10.3389/fimmu.2020.603594 747 Eikelenboom, P., Hoozemans, J. J., Veerhuis, R., van Exel, E., Rozemuller, A. J., & van Gool, 748 W. A. (2012). Whether, when and how chronic inflammation increases the risk of 749 750 developing late-onset Alzheimer's disease. Alzheimers Res Ther, 4(3), 15. 751 https://doi.org/10.1186/alzrt118 Eisenberg, T., Knauer, H., Schauer, A., Buttner, S., Ruckenstuhl, C., Carmona-Gutierrez, D., 752 753 Ring, J., Schroeder, S., Magnes, C., Antonacci, L., Fussi, H., Deszcz, L., Hartl, R., Schraml, E., Criollo, A., Megalou, E., Weiskopf, D., Laun, P., Heeren, G., Breitenbach, 754 755 M., Grubeck-Loebenstein, B., Herker, E., Fahrenkrog, B., Frohlich, K. U., Sinner, F., 756 Tavernarakis, N., Minois, N., Kroemer, G., & Madeo, F. (2009). Induction of autophagy by spermidine promotes longevity. Nat Cell Biol, 11(11), 1305-1314. 757 https://doi.org/10.1038/ncb1975 758 759 Erny, D., Hrabe de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermohlen, O., 760 Chun, E., Garrett, W. S., McCoy, K. D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, 761 I., & Prinz, M. (2015). Host microbiota constantly control maturation and function of 762 microglia in the CNS. Nat Neurosci, 18(7), 965-977. https://doi.org/10.1038/nn.4030 763 Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential 764 765 contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci, 69 Suppl 1, S4-9. https://doi.org/10.1093/gerona/glu057 766 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a 767 new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol, 768 769 14(10), 576-590. https://doi.org/10.1038/s41574-018-0059-4 770 Frasca, D., & Blomberg, B. B. (2016). Inflammaging decreases adaptive and innate immune 771 responses in mice and humans. Biogerontology, 17(1), 7-19. 772 https://doi.org/10.1007/s10522-015-9578-8 Frohlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jacan, A., Wagner, B., Zinser, E., 773 774 Bordag, N., Magnes, C., Frohlich, E., Kashofer, K., Gorkiewicz, G., & Holzer, P. 775 (2016). Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. 140-155. 776 Brain **Behav** Immun, 56, 777 https://doi.org/10.1016/j.bbi.2016.02.020 778 Fu, B. C., Hullar, M. A. J., Randolph, T. W., Franke, A. A., Monroe, K. R., Cheng, I., Wilkens, L. R., Shepherd, J. A., Madeleine, M. M., Le Marchand, L., Lim, U., & Lampe, J. W. 779 (2020). Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine 780 781 with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am J Clin Nutr, 111(6), 1226-1234. 782 https://doi.org/10.1093/ajcn/ngaa015 783

- Fujikake, N., Shin, M., & Shimizu, S. (2018). Association Between Autophagy and 784 785 Neurodegenerative Diseases. Front Neurosci, 12, 255. https://doi.org/10.3389/fnins.2018.00255 786
- Gan, L., Cookson, M. R., Petrucelli, L., & La Spada, A. R. (2018). Converging pathways in 787 neurodegeneration, from genetics to mechanisms. Nat Neurosci, 21(10), 1300-1309. 788 https://doi.org/10.1038/s41593-018-0237-7 789
- Gao, S., Casey, A. E., Sargeant, T. J., & Makinen, V. P. (2018). Genetic variation within 790 endolysosomal system is associated with late-onset Alzheimer's disease. Brain, 141(9), 791 792 2711-2720. https://doi.org/10.1093/brain/awy197
- 793 Ghosh, T. S., Rampelli, S., Jeffery, I. B., Santoro, A., Neto, M., Capri, M., Giampieri, E., Jennings, A., Candela, M., Turroni, S., Zoetendal, E. G., Hermes, G. D. A., Elodie, C., 794 795 Meunier, N., Brugere, C. M., Pujos-Guillot, E., Berendsen, A. M., De Groot, L., 796 Feskins, E. J. M., Kaluza, J., Pietruszka, B., Bielak, M. J., Comte, B., Maijo-Ferre, M., Nicoletti, C., De Vos, W. M., Fairweather-Tait, S., Cassidy, A., Brigidi, P., Franceschi, 797 C., & O'Toole, P. W. (2020). Mediterranean diet intervention alters the gut microbiome 798 in older people reducing frailty and improving health status: the NU-AGE 1-year 799 800 dietary intervention across five European countries. Gut, 69(7), 1218-1228. https://doi.org/10.1136/gutjnl-2019-319654 801
- Ghoshal, U., Shukla, R., Srivastava, D., & Ghoshal, U. C. (2016). Irritable Bowel Syndrome, 802 803 Particularly the Constipation-Predominant Form, Involves an Increase in Methanobrevibacter smithii, Which Is Associated with Higher Methane Production. 804 Gut Liver, 10(6), 932-938. https://doi.org/10.5009/gnl15588 805
- 806 Giunta, B., Fernandez, F., Nikolic, W. V., Obregon, D., Rrapo, E., Town, T., & Tan, J. (2008). Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation, 5, 51. 807 https://doi.org/10.1186/1742-2094-5-51 808
- 809 Grande, G., Marengoni, A., Vetrano, D. L., Roso-Llorach, A., Rizzuto, D., Zucchelli, A., Qiu, C., Fratiglioni, L., & Calderon-Larranaga, A. (2021). Multimorbidity burden and 810 dementia risk in older adults: The role of inflammation and genetics. Alzheimers 811 Dement, 17(5), 768-776. https://doi.org/10.1002/alz.12237 812
- Gubert, C., Choo, J. M., Love, C. J., Kodikara, S., Masson, B. A., Liew, J. J. M., Wang, Y., 813 Kong, G., Narayana, V. K., Renoir, T., Le Cao, K. A., Rogers, G. B., & Hannan, A. J. 814 (2022). Faecal microbiota transplant ameliorates gut dysbiosis and cognitive deficits in 815 Huntington's 816 disease mice. Brain Commun. 4(4),fcac205. https://doi.org/10.1093/braincomms/fcac205 817
- Gueli, M. C., & Taibi, G. (2013). Alzheimer's disease: amino acid levels and brain metabolic 818 819 status. Neurol Sci, 34(9), 1575-1579. https://doi.org/10.1007/s10072-013-1289-9
- Haines, A., Metz, G., Dilawari, J., Blendis, L., & Wiggins, H. (1977). Breath-methane in 820 patients with cancer of the large bowel. Lancet, 2(8036). 481-483. 821 822 https://doi.org/10.1016/s0140-6736(77)91605-1
- Harada, C. N., Natelson Love, M. C., & Triebel, K. L. (2013). Normal cognitive aging. Clin 823 Geriatr Med, 29(4), 737-752. https://doi.org/10.1016/j.cger.2013.07.002 824
- Henon, H., Durieu, I., Guerouaou, D., Lebert, F., Pasquier, F., & Leys, D. (2001). Poststroke 825 dementia: incidence and relationship to prestroke cognitive decline. Neurology, 57(7), 826 1216-1222. https://doi.org/10.1212/wnl.57.7.1216 827
- 828 Hoogland, I. C. M., Westhoff, D., Engelen-Lee, J. Y., Melief, J., Valls Seron, M., Houben-Weerts, J., Huitinga, I., van Westerloo, D. J., van der Poll, T., van Gool, W. A., & van 829 de Beek, D. (2018). Microglial Activation After Systemic Stimulation With 830 831 Lipopolysaccharide and Escherichia coli. Front Cell Neurosci, 12, 110. https://doi.org/10.3389/fncel.2018.00110 832

- Hosomi, K., Saito, M., Park, J., Murakami, H., Shibata, N., Ando, M., Nagatake, T., Konishi, 833 834 K., Ohno, H., Tanisawa, K., Mohsen, A., Chen, Y. A., Kawashima, H., Natsume-Kitatani, Y., Oka, Y., Shimizu, H., Furuta, M., Tojima, Y., Sawane, K., Saika, A., 835 Kondo, S., Yonejima, Y., Takeyama, H., Matsutani, A., Mizuguchi, K., Miyachi, M., 836 & Kunisawa, J. (2022). Oral administration of Blautia wexlerae ameliorates obesity and 837 type 2 diabetes via metabolic remodeling of the gut microbiota. Nat Commun, 13(1), 838 4477. https://doi.org/10.1038/s41467-022-32015-7 839
- Jackson, M. A., Jeffery, I. B., Beaumont, M., Bell, J. T., Clark, A. G., Ley, R. E., O'Toole, P. 840 841 W., Spector, T. D., & Steves, C. J. (2016). Signatures of early frailty in the gut 842 microbiota. Genome Med, 8(1), 8. https://doi.org/10.1186/s13073-016-0262-7
- Jimenez-Jimenez, F. J., Molina, J. A., Gomez, P., Vargas, C., de Bustos, F., Benito-Leon, J., 843 844 Tallon-Barranco, A., Orti-Pareja, M., Gasalla, T., & Arenas, J. (1998). 845 Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's Transm 846 disease. JNeural (Vienna). 105(2-3). 269-277. https://doi.org/10.1007/s007020050056 847
- Jorm, A. F., Mackinnon, A. J., Henderson, A. S., Scott, R., Christensen, H., Korten, A. E., 848 Cullen, J. S., & Mulligan, R. (1995). The Psychogeriatric Assessment Scales: a multi-849 dimensional alternative to categorical diagnoses of dementia and depression in the 850 elderly. Psychol Med, 25(3), 447-460. https://doi.org/10.1017/s0033291700033377 851
- 852 Kaelberer, M. M., Buchanan, K. L., Klein, M. E., Barth, B. B., Montoya, M. M., Shen, X., & Bohorquez, D. V. (2018). A gut-brain neural circuit for nutrient sensory transduction. 853 854 Science, 361(6408). https://doi.org/10.1126/science.aat5236
- Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M., & Kim, C. H. (2013). Short-chain fatty 855 acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory 856 responses mice. Gastroenterology, 145(2), 396-406 e391-310. 857 in https://doi.org/10.1053/j.gastro.2013.04.056 858
- Kim, M. S., Kim, Y., Choi, H., Kim, W., Park, S., Lee, D., Kim, D. K., Kim, H. J., Choi, H., 859 Hyun, D. W., Lee, J. Y., Choi, E. Y., Lee, D. S., Bae, J. W., & Mook-Jung, I. (2020). 860 Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's 861 disease animal model. Gut, 69(2), 283-294. https://doi.org/10.1136/gutjnl-2018-862 317431 863
- Kim, S., Goel, R., Kumar, A., Qi, Y., Lobaton, G., Hosaka, K., Mohammed, M., Handberg, E. 864 M., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018). Imbalance of gut 865 microbiome and intestinal epithelial barrier dysfunction in patients with high blood 866 pressure. Clin Sci (Lond), 132(6), 701-718. https://doi.org/10.1042/CS20180087 867
- 868 Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., & Paul, S. M. (2004). Apolipoprotein E promotes astrocyte 869 870 colocalization and degradation of deposited amyloid-beta peptides. Nat Med, 10(7), 871 719-726. https://doi.org/10.1038/nm1058
- Komanduri, M., Savage, K., Lea, A., McPhee, G., Nolidin, K., Deleuil, S., Stough, C., & 872 Gondalia, S. (2021). The Relationship between Gut Microbiome and Cognition in Older 873 874 Australians. Nutrients, 14(1). https://doi.org/10.3390/nu14010064
- Kong, G., Ellul, S., Narayana, V. K., Kanojia, K., Ha, H. T. T., Li, S., Renoir, T., Cao, K. L., 875 & Hannan, A. J. (2021). An integrated metagenomics and metabolomics approach 876 877 implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease. Neurobiol Dis, 148, 105199. https://doi.org/10.1016/j.nbd.2020.105199 878
- Lai, W. T., Zhao, J., Xu, S. X., Deng, W. F., Xu, D., Wang, M. B., He, F. S., Liu, Y. H., Guo, 879 880 Y. Y., Ye, S. W., Yang, Q. F., Zhang, Y. L., Wang, S., Li, M. Z., Yang, Y. J., Liu, T. B., Tan, Z. M., Xie, X. H., & Rong, H. (2021). Shotgun metagenomics reveals both 881 taxonomic and tryptophan pathway differences of gut microbiota in bipolar disorder 882

with current major depressive episode patients. J Affect Disord, 278, 311-319. 883 https://doi.org/10.1016/j.jad.2020.09.010 884

- Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. Nat 885 Methods, 9(4), 357-359. https://doi.org/10.1038/nmeth.1923 886
- Larroya, A., Pantoja, J., Codoner-Franch, P., & Cenit, M. C. (2021). Towards Tailored Gut 887 Microbiome-Based and Dietary Interventions for Promoting the Development and 888 Maintenance of Healthy Brain. Front Pediatr. 9. 705859. 889 a https://doi.org/10.3389/fped.2021.705859 890
- Lazarou, M., Sliter, D. A., Kane, L. A., Sarraf, S. A., Wang, C., Burman, J. L., Sideris, D. P., 891 Fogel, A. I., & Youle, R. J. (2015). The ubiquitin kinase PINK1 recruits autophagy 892 893 receptors to induce mitophagy. Nature, 524(7565), 309-314. https://doi.org/10.1038/nature14893 894
- Li, C., Luan, Z., Zhao, Y., Chen, J., Yang, Y., Wang, C., Jing, Y., Qi, S., Li, Z., Guo, H., Xu, 895 W., Zhao, B., Wu, C., Wang, S., Yang, Y., & Sun, G. (2022). Deep insights into the gut 896 microbial community of extreme longevity in south Chinese centenarians by ultra-deep 897 metagenomics and large-scale culturomics. NPJ Biofilms Microbiomes, 8(1), 28. 898 899 https://doi.org/10.1038/s41522-022-00282-3
- Lin, C. H., Yang, H. T., & Lane, H. Y. (2019). D-glutamate, D-serine, and D-alanine differ in 900 their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive 901 902 impairment. Pharmacol Biochem Behav, 185, 172760. https://doi.org/10.1016/j.pbb.2019.172760 903
- Lin, C. H., Yang, S. Y., Horng, H. E., Yang, C. C., Chieh, J. J., Chen, H. H., Liu, B. H., & 904 905 Chiu, M. J. (2017). Plasma alpha-synuclein predicts cognitive decline in Parkinson's disease. J Neurol Neurosurg Psychiatry, 88(10), 818-824. https://doi.org/10.1136/jnnp-906 2016-314857 907
- 908 Lin, Y. T., Seo, J., Gao, F., Feldman, H. M., Wen, H. L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., Rueda, R., Kritskiy, O., Abdurrob, F., Peng, Z., Milo, B., Yu, 909 C. J., Elmsaouri, S., Dey, D., Ko, T., Yankner, B. A., & Tsai, L. H. (2018). APOE4 910 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's 911 Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron, 98(6), 1141-912 913 1154 e1147. https://doi.org/10.1016/j.neuron.2018.05.008
- Lind, K. E., Raban, M. Z., Brett, L., Jorgensen, M. L., Georgiou, A., & Westbrook, J. I. (2020). 914 Measuring the prevalence of 60 health conditions in older Australians in residential 915 aged care with electronic health records: a retrospective dynamic cohort study. Popul 916 Health Metr, 18(1), 25. https://doi.org/10.1186/s12963-020-00234-z 917
- Liu, C. C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C. W., & Bu, G. (2017). ApoE4 918 Accelerates Early Seeding of Amyloid Pathology. Neuron, 96(5), 1024-1032 e1023. 919 920 https://doi.org/10.1016/j.neuron.2017.11.013
- 921 Liu, X., Mao, B., Gu, J., Wu, J., Cui, S., Wang, G., Zhao, J., Zhang, H., & Chen, W. (2021). Blautia-a new functional genus with potential probiotic properties? Gut Microbes, 922 13(1), 1-21. https://doi.org/10.1080/19490976.2021.1875796 923
- Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., 924 Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, 925 L. N., Howard, R., Kales, H. C., Kivimaki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., 926 927 Ritchie, K., Rockwood, K., Sampson, E. L., Samus, Q., Schneider, L. S., Selbaek, G., Teri, L., & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 928 report of the Lancet Commission. Lancet, 396(10248), 413-446. 929 930 https://doi.org/10.1016/S0140-6736(20)30367-6

- Lozupone, C., & Knight, R. (2005). UniFrac: a new phylogenetic method for comparing 931 932 microbial communities. Appl Environ Microbiol, 71(12), 8228-8235. https://doi.org/10.1128/AEM.71.12.8228-8235.2005 933
- 934 Luo, R., Su, L. Y., Li, G., Yang, J., Liu, Q., Yang, L. X., Zhang, D. F., Zhou, H., Xu, M., Fan, Y., Li, J., & Yao, Y. G. (2020). Activation of PPARA-mediated autophagy reduces 935 Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 936 16(1), 52-69. https://doi.org/10.1080/15548627.2019.1596488 937
- Lynn, M. A., Eden, G., Ryan, F. J., Bensalem, J., Wang, X., Blake, S. J., Choo, J. M., Chern, 938 Y. T., Sribnaia, A., James, J., Benson, S. C., Sandeman, L., Xie, J., Hassiotis, S., Sun, 939 940 E. W., Martin, A. M., Keller, M. D., Keating, D. J., Sargeant, T. J., Proud, C. G., Wesselingh, S. L., Rogers, G. B., & Lynn, D. J. (2021). The composition of the gut 941 microbiota following early-life antibiotic exposure affects host health and longevity in 942 943 later life. Cell Rep, 36(8), 109564. https://doi.org/10.1016/j.celrep.2021.109564
- Maczulak, A. E., Wolin, M. J., & Miller, T. L. (1989). Increase in colonic methanogens and 944 total anaerobes in aging rats. Appl Environ Microbiol, 55(10), 2468-2473. 945 https://doi.org/10.1128/aem.55.10.2468-2473.1989 946
- 947 Manderino, L., Carroll, I., Azcarate-Peril, M. A., Rochette, A., Heinberg, L., Peat, C., Steffen, K., Mitchell, J., & Gunstad, J. (2017). Preliminary Evidence for an Association 948 Between the Composition of the Gut Microbiome and Cognitive Function in 949 950 Neurologically Healthy Older Adults. J Int Neuropsychol Soc, 23(8), 700-705. https://doi.org/10.1017/S1355617717000492 951
- Marx, W., McGuinness, A. J., Rocks, T., Ruusunen, A., Cleminson, J., Walker, A. J., Gomes-952 953 da-Costa, S., Lane, M., Sanches, M., Diaz, A. P., Tseng, P. T., Lin, P. Y., Berk, M., Clarke, G., O'Neil, A., Jacka, F., Stubbs, B., Carvalho, A. F., Quevedo, J., Soares, J. C., 954 & Fernandes, B. S. (2021). The kynurenine pathway in major depressive disorder, 955 956 bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry, 26(8), 4158-4178. https://doi.org/10.1038/s41380-020-00951-9 957
- Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., & Roytta, M. (2000). Alpha-958 959 synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment Parkinson's 960 in disease. Acta Neuropathol, 100(3). 285-290. https://doi.org/10.1007/s004019900168 961
- Meyer, K., Lulla, A., Debroy, K., Shikany, J. M., Yaffe, K., Meirelles, O., & Launer, L. J. 962 (2022). Association of the Gut Microbiota With Cognitive Function in Midlife. JAMA 963 Netw Open, 5(2), e2143941. https://doi.org/10.1001/jamanetworkopen.2021.43941 964
- Mizushima, N. (2004). Methods for monitoring autophagy. Int J Biochem Cell Biol, 36(12), 965 966 2491-2502. https://doi.org/10.1016/j.biocel.2004.02.005
- Motulsky, H. J., & Brown, R. E. (2006). Detecting outliers when fitting data with nonlinear 967 968 regression - a new method based on robust nonlinear regression and the false discovery 969 rate. BMC Bioinformatics, 7, 123. https://doi.org/10.1186/1471-2105-7-123
- 970 Murley, A. G., Rouse, M. A., Jones, P. S., Ye, R., Hezemans, F. H., O'Callaghan, C., Frangou, P., Kourtzi, Z., Rua, C., Carpenter, T. A., Rodgers, C. T., & Rowe, J. B. (2020). GABA 971 972 and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. Brain, 143(11), 3449-3462. https://doi.org/10.1093/brain/awaa305 973
- Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. Nat Med, 19(8), 983-974 975 997. https://doi.org/10.1038/nm.3232
- 976 Oksanen, J., Simpson, G. L., Blanchet, F. G., Kindt, R., Legendre, P., Minchin, P. R., O'Hara, 977 R. B., Solymos, P., Stevens, M. H., Szoecs, E., Wagner, H., Barbour, M., Bedward, M., 978 Bolker, B., Borcard, D., Carvalho, G., Chirico, M., De Caceres, M., Durand, S., Evangelista, H. B. A., FitzJohn, R., Friendly, M., Furneaux, B., Hannigan, G., Hill, M. 979 O., Lahti, L., McGlinn, D., Ouellette, M., Cunha, E. R., Smith, T., Stier, A., Ter Braak, 980

medRxiv preprint doi: https://doi.org/10.1101/2023.03.06.23286878; this version posted January 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

C. J. F., and Weedon J. (2022). vegan: Community Ecology Package. In R package

It is made available under	°a CC-BY-NC-NE	0 4.0 International license.	

981

982	version 2.6-2. <u>https://CRAN.R-project.org/package=vegan</u>
983	Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut
984	microbiome: major fermentation by-products and their impact on host health.
985	Microbiome, 7(1), 91. https://doi.org/10.1186/s40168-019-0704-8
986	Parcon, P. A., Balasubramaniam, M., Ayyadevara, S., Jones, R. A., Liu, L., Shmookler Reis,
987	R. J., Barger, S. W., Mrak, R. E., & Griffin, W. S. T. (2018). Apolipoprotein E4 inhibits
988	autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers
989	Dement, 14(2), 230-242. https://doi.org/10.1016/j.jalz.2017.07.754
990	Parker, B. J., Wearsch, P. A., Veloo, A. C. M., & Rodriguez-Palacios, A. (2020). The Genus
991	Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and
992	Mental Health. Front Immunol, 11, 906. https://doi.org/10.3389/fimmu.2020.00906
993	Peet, R. K. (1974). The Measurement of Species Diversity. Annual Review of Ecology and
994	Systematics, 5(1), 285-307. https://doi.org/10.1146/annurev.es.05.110174.001441
995	Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A.,
996	Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J. M., Guo, J. Y., Lattime,
997	E., Rabinowitz, J. D., & White, E. (2018). Autophagy maintains tumour growth through
998	circulating arginine. <i>Nature</i> , 563(7732), 569-573. <u>https://doi.org/10.1038/s41586-018-</u>
999	<u>0697-7</u>
1000	Pugin, B., Barcik, W., Westermann, P., Heider, A., Wawrzyniak, M., Hellings, P., Akdis, C.
1001	A., & O'Mahony, L. (2017). A wide diversity of bacteria from the human gut produces
1002	and degrades biogenic amines. Microb Ecol Health Dis, 28(1), 1353881.
1003	https://doi.org/10.1080/16512235.2017.1353881
1004	Rodriguez-Palacios, A., Conger, M., Hopperton, A., Ezeji, J. C., Erkkila, H. L., Fiocchi, C., &
1005	Cominelli, F. (2019). 25 IDENTIFICATION OF PATHOGENIC BACTERIA IN
1005	SEVERE CROHN'S DISEASE. Inflammatory Bowel Diseases, 25(Supplement_1),
	STO-STO. https://doi.org/10.1093/ibd/izy393.175
1007	
1008	Rogers, G. B., Keating, D. J., Young, R. L., Wong, M. L., Licinio, J., & Wesselingh, S. (2016).
1009	From gut dysbiosis to altered brain function and mental illness: mechanisms and
1010	pathways. Mol Psychiatry, 21(6), 738-748. https://doi.org/10.1038/mp.2016.50
1011	Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C.,
1012	Schretter, C. E., Rocha, S., Gradinaru, V., Chesselet, M. F., Keshavarzian, A., Shannon,
1013	K. M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., & Mazmanian, S. K.
1014	(2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of
1015	Parkinson's Disease. Cell, 167(6), 1469-1480 e1412.
1016	https://doi.org/10.1016/j.cell.2016.11.018
1017	Sankowski, R., Mader, S., & Valdes-Ferrer, S. I. (2015). Systemic inflammation and the brain:
1018	novel roles of genetic, molecular, and environmental cues as drivers of
1019	neurodegeneration. Front Cell Neurosci, 9, 28.
1020	https://doi.org/10.3389/fncel.2015.00028
1021	Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The Central
1022	Nervous System and the Gut Microbiome. Cell, 167(4), 915-932.
1023	https://doi.org/10.1016/j.cell.2016.10.027
1024	Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S.,
1025	Grinberg, L. T., Rojas, J. C., Gallardo, G., Wang, K., Roh, J., Robinson, G., Finn, M.
1026	B., Jiang, H., Sullivan, P. M., Baufeld, C., Wood, M. W., Sutphen, C., McCue, L.,
1027	Xiong, C., Del-Aguila, J. L., Morris, J. C., Cruchaga, C., Alzheimer's Disease
1028	Neuroimaging, I., Fagan, A. M., Miller, B. L., Boxer, A. L., Seeley, W. W., Butovsky,
1028	O., Barres, B. A., Paul, S. M., & Holtzman, D. M. (2017). ApoE4 markedly exacerbates
1023	O., Darros, D. A., I aur, S. W., & HORZMan, D. W. (2017). Apolt4 marketily exactibates

- tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*, 549(7673),
- 1031 523-527. <u>https://doi.org/10.1038/nature24016</u>
  1032 Shoubridge, A. P., Choo, J. M., Martin, A. M., Keating, D. J., Wong, M. L., Licinio, J., & 1033 Rogers, G. B. (2022). The gut microbiome and mental health: advances in research and
- 1035
   Rogers, G. B. (2022). The gut interobolone and mental nearth. advances in research and


   1034
   emerging priorities. Mol Psychiatry, 27(4), 1908-1919. <a href="https://doi.org/10.1038/s41380-022-01479-w">https://doi.org/10.1038/s41380-</a>


   1035
   022-01479-w
- Soto, M., Herzog, C., Pacheco, J. A., Fujisaka, S., Bullock, K., Clish, C. B., & Kahn, C. R.
  (2018). Gut microbiota modulate neurobehavior through changes in brain insulin
  sensitivity and metabolism. *Mol Psychiatry*, 23(12), 2287-2301.
  https://doi.org/10.1038/s41380-018-0086-5
- Stadlbauer, V., Engertsberger, L., Komarova, I., Feldbacher, N., Leber, B., Pichler, G., Fink,
   N., Scarpatetti, M., Schippinger, W., Schmidt, R., & Horvath, A. (2020). Dysbiosis, gut
   barrier dysfunction and inflammation in dementia: a pilot study. *BMC Geriatr*, 20(1),
   248. <u>https://doi.org/10.1186/s12877-020-01644-2</u>
- 1044Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018). Inflammation in CNS1045neurodegenerativediseases.1046https://doi.org/10.1111/imm.12922
- Strandwitz, P. (2018). Neurotransmitter modulation by the gut microbiota. *Brain Res*, *1693*(Pt
   B), 128-133. <u>https://doi.org/10.1016/j.brainres.2018.03.015</u>
- Sud, M., Fahy, E., Cotter, D., Azam, K., Vadivelu, I., Burant, C., Edison, A., Fiehn, O.,
  Higashi, R., Nair, K. S., Sumner, S., & Subramaniam, S. (2016). Metabolomics
  Workbench: An international repository for metabolomics data and metadata,
  metabolite standards, protocols, tutorials and training, and analysis tools. *Nucleic Acids Res*, 44(D1), D463-470. <u>https://doi.org/10.1093/nar/gkv1042</u>
- Sun, M. F., Zhu, Y. L., Zhou, Z. L., Jia, X. B., Xu, Y. D., Yang, Q., Cui, C., & Shen, Y. Q. 1054 1055 (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha 1056 48-60. signaling Behav 70, 1057 pathway. Brain Immun, https://doi.org/10.1016/j.bbi.2018.02.005 1058
- Suzuki, H., Yamashiro, D., Ogawa, S., Kobayashi, M., Cho, D., Iizuka, A., Tsukamoto-Yasui,
  M., Takada, M., Isokawa, M., Nagao, K., & Fujiwara, Y. (2020). Intake of Seven
  Essential Amino Acids Improves Cognitive Function and Psychological and Social
  Function in Middle-Aged and Older Adults: A Double-Blind, Randomized, PlaceboControlled Trial. *Front Nutr*, 7, 586166. <a href="https://doi.org/10.3389/fnut.2020.586166">https://doi.org/10.3389/fnut.2020.586166</a>
- Takahashi, K., Nishida, A., Fujimoto, T., Fujii, M., Shioya, M., Imaeda, H., Inatomi, O.,
  Bamba, S., Sugimoto, M., & Andoh, A. (2016). Reduced Abundance of ButyrateProducing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. *Digestion*, 93(1), 59-65. https://doi.org/10.1159/000441768
- 1068 Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., Kramer, P., Woltjer, R., 1069 Kukull, W., Nelson, P. T., Jicha, G. A., Neltner, J. H., Galasko, D., Masliah, E., 1070 1071 Trojanowski, J. Q., Schellenberg, G. D., Yearout, D., Huston, H., Fritts-Penniman, A., Mata, I. F., Wan, J. Y., Edwards, K. L., Montine, T. J., & Zabetian, C. P. (2012). GBA 1072 mutations increase risk for Lewy body disease with and without Alzheimer disease 1073 1074 pathology. Neurology, 79(19). 1944-1950. https://doi.org/10.1212/WNL.0b013e3182735e9a 1075
- Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nystrom, S., Nilsson, K. P., Song, W. M., Zhou, Y.,
  Reinartz, M., Choi, S., Jiang, H., Stewart, F. R., Anderson, E., Wang, Y., Colonna, M.,
  & Holtzman, D. M. (2018). ApoE facilitates the microglial response to amyloid plaque
  pathology. *J Exp Med*, *215*(4), 1047-1058. <u>https://doi.org/10.1084/jem.20171265</u>

- Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, 1080 C., Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., 1081 Zhernakova, A., Vieira-Silva, S., & Raes, J. (2019). The neuroactive potential of the 1082 1083 human gut microbiota in quality of life and depression. Nat Microbiol, 4(4), 623-632. https://doi.org/10.1038/s41564-018-0337-x 1084
- van Soest, A. P. M., Hermes, G. D. A., Berendsen, A. A. M., van de Rest, O., Zoetendal, E. G., 1085 Fuentes, S., Santoro, A., Franceschi, C., de Groot, L., & de Vos, W. M. (2020). 1086 Associations between Pro- and Anti-Inflammatory Gastro-Intestinal Microbiota, Diet, 1087 1088 and Cognitive Functioning in Dutch Healthy Older Adults: The NU-AGE Study. Nutrients, 12(11). https://doi.org/10.3390/nu12113471 1089
- Verdi, S., Jackson, M. A., Beaumont, M., Bowyer, R. C. E., Bell, J. T., Spector, T. D., & Steves, 1090 C. J. (2018). An Investigation Into Physical Frailty as a Link Between the Gut 1091 1092 Microbiome and Cognitive Health. Front Aging Neurosci, 10. 398. https://doi.org/10.3389/fnagi.2018.00398 1093
- Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. 1094 C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., Bendlin, B. B., & Rey, 1095 1096 F. E. (2017). Gut microbiome alterations in Alzheimer's disease. Sci Rep, 7(1), 13537. 1097 https://doi.org/10.1038/s41598-017-13601-y
- Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., & Zhao, L. (2012). 1098 1099 Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J, 6(2), 320-329. https://doi.org/10.1038/ismej.2011.109 1100
- 1101 Wasser, C. I., Mercieca, E. C., Kong, G., Hannan, A. J., McKeown, S. J., Glikmann-Johnston, 1102 Y., & Stout, J. C. (2020). Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes. Brain Commun, 2(2), 1103 fcaa110. https://doi.org/10.1093/braincomms/fcaa110 1104
- 1105 Weaver, G. A., Krause, J. A., Miller, T. L., & Wolin, M. J. (1986). Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and 1106 diverticulosis. Gut, 27(6), 698-704. https://doi.org/10.1136/gut.27.6.698 1107
- Wu, L., Zeng, T., Zinellu, A., Rubino, S., Kelvin, D. J., & Carru, C. (2019). A Cross-Sectional 1108 1109 Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems, 4(4). https://doi.org/10.1128/mSystems.00325-19 1110
- Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, 1111 R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015). Indigenous bacteria from the gut 1112 microbiota regulate host serotonin biosynthesis. 1113 Cell. 161(2), 264-276. 1114 https://doi.org/10.1016/j.cell.2015.02.047
- 1115 Ye, B. S., Seo, S. W., Kim, J. H., Kim, G. H., Cho, H., Noh, Y., Kim, H. J., Yoon, C. W., Woo, S. Y., Kim, S. H., Park, H. K., Kim, S. T., Choe, Y. S., Lee, K. H., Kim, J. S., Oh, S. 1116 J., Kim, C., Weiner, M., Lee, J. H., & Na, D. L. (2015). Effects of amyloid and vascular 1117 1118 markers on cognitive decline in subcortical vascular dementia. Neurology, 85(19), 1687-1693. https://doi.org/10.1212/WNL.000000000002097 1119
- Ye, L., Bae, M., Cassilly, C. D., Jabba, S. V., Thorpe, D. W., Martin, A. M., Lu, H. Y., Wang, 1120 J., Thompson, J. D., Lickwar, C. R., Poss, K. D., Keating, D. J., Jordt, S. E., Clardy, J., 1121 Liddle, R. A., & Rawls, J. F. (2021). Enteroendocrine cells sense bacterial tryptophan 1122 catabolites to activate enteric and vagal neuronal pathways. Cell Host Microbe, 29(2), 1123 179-196 e179. https://doi.org/10.1016/j.chom.2020.11.011 1124


1125








Adjusted odds ratio with 95% confidence interval




Adjusted odds ratio with 95% confidence interval





Mild

Moderate

Severe







## **Figures and Tables**

**Table 1.** Study Cohort Characteristics by Severity of Cognitive Impairment.

<sup>#</sup>Extracted from Aged Care Funding Instrument data.

^Memory support units (also known as dementia units/wards, memory care, or special care units) are secure areas within long-term care facilities specially designed to accommodate residents with dementia.

\*Medication use defined as two or more supplies of the same medication within 90 days prior to stool collection.

Demographic	Mild	Mild Moderate		Total	
Demographic	( <b>n=46</b> )	(n=58)	(n=55)	( <b>n=159</b> )	
Age (years):					
Median (IQR)	87.5 (81.3;93.6)	90.3 (83.7;95.0)	87.9 (82.0;93.0)	88.7(82.1; 93.5)	
Sex: n (%)					
Female	27 (58.7)	42 (72.4)	40 (72.7)	109 (68.6)	
Male	19 (41.3)	16 (27.6)	15 (27.3)	50 (31.4)	
PAS-CIS:					
Median (IQR)	6.6 (5.0;8.0)	11.0 (11.0;12.8)	18.0 (17.0;18.8)	10.8 (7.0;18.0)	
Time between CI					
assessment and stool					
collection (days):					
Median (IQR)	345.5 (148.5,654.5)	421.5 (182.3,734.3)	487.0 (252.0,909.0)	437.0 (185.0,741.0)	
Time since entry to facility (days):					
Median (IQR)	500 (253.0,947.5)	704 (299.0.983.0)	962 (502.0,1198.0)	681 (360.0,1015.0)	
Dementia diagnosis:	500 (255.0,517.5)	701 (2)).0,903.0)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	001 (000.0,1010.0)	
% (n) <sup>#</sup>	8.7 (4)	56.9 (33)	96.4 (53)	56.6 (90)	
Memory Support					
<b>Unit^:</b> n (%)	0 (0.0)	4 (6.9)	19 (34.5)	23 (14.5)	
Meal texture: n (%)					
Regular	38 (82.6)	44 (75.9)	30 (54.5)	112 (70.4)	
Soft/smooth	8 (17.4)	14 (24.1)	25 (45.5)	47 (29.6)	
Liquid texture: n (%)	12 (01.2)	54 (02.1)	40 (00 1)	145 (01.0)	
Normal/thin	42 (91.3)	54 (93.1)	49 (89.1)	145 (91.2)	
Thick Antibiotics (at least 2	4 (8.7)	4 (6.9)	6 (10.9)	14 (8.8)	
supplied <sup>*</sup> ): n (%)	10 (21.7)	7 (12.1)	5 (9.1)	22 (13.8)	
Proton pump	10(21.7)	/ (12.1)	J (7.1)	22 (13.0)	
inhibitors (at least 2					
supplied <sup>*</sup> ): n (%)	23 (50.0)	23 (39.7)	12 (21.8)	58 (36.5)	
Opioids (at least 2	× /	× ,		× /	
supplied <sup>*</sup> ): n (%)	8 (17.4)	12 (20.7)	14 (25.5)	34 (21.4)	
Laxatives (at least 2					
<b>supplied</b> *): n (%)	6 (13.0)	6 (10.3)	9 (16.4)	21 (13.2)	

**Table 2.** Permutational ANOVA of the gut microbiome by severity of cognitive impairment.

<sup>a</sup>Time since cognitive impairment assessment + age + sex+ antibiotic use + proton pump inhibitor use + opioid use + laxative use + recorded medication history + meal texture + liquid texture.

^Permutation p-value generated with a PERMANOVA.

\*Degrees of freedom = 2.

	Unadjusted Model			Multivariate-adjusted Model <sup>a</sup>			
Main Test	Pseudo-F Ratio	R <sup>2</sup>	p(perm)^	Pseudo-F Ratio	R <sup>2</sup>	p(perm)^	
Cognitive Impairment*	1.9646	0.0246	0.0002	1.815	0.0221	0.0003	
Pairwise Test	t		p(perm)^	t		p(perm)^	
Mild v Moderate	1.0596		0.2583	1.1135		0.1478	
Mild v Severe	1.4474		0.0017	1.4228		0.0023	
Moderate v Severe	1.6304		0.0002	1.5265		0.0003	